Serial No.: 10/539,208 Attorney's Docket No.: B&B-135

Art Unit: Unknown Page 2

Inventor: David RAAB et al.

## Amendments to the Specification:

On page 41, please replace the paragraph beginning on line 7 with the following:

The intention is to ascertain the optimal DNA sequence (SEQ ID NO: 9) pertaining to the (fictional) amino acid sequence AASeq1 (SEQ ID NO:10) from below. A conventional back-translation with optimization for optimal codon usage serves as reference.

On page 43, please replace the paragraphs beginning on line 11 and ending on line 35 with the following:

An optimization only for optimal codon usage results in the following sequence:

It is characterized by the following properties:

- highly repetitive, caused by the amino acid sequence F\_I\_I\_K\_N (residues 3-7 and 9-13 of SEQ ID NO: 10) which appears twice (the repetitive sequence (bases 7-21 and 25-39 of SEQ ID NO:9) with the highest score (18) is shown):
  - 19 AACATGTTTATTAAAAAC
  - 2 AACA-GTTTATTATTAAAAAC
  - GC content: 21.4%
  - the Nla III recognition sequence CATG is present
  - average codon usage 100

Serial No.: 10/539,208 Attorney's Docket No.: B&B-135

Art Unit: Unknown Page 3 Inventor: David RAAB et al.

If the optimization is carried out according to the algorithm of the invention with the abovementioned assessment functions and parameters, the following DNA sequence is obtained:

On page 45, please replace the paragraph beginning on line 24 with the following:

The CDS are in this case arranged according to decreasing total score, i.e. the first codon of the first CDS shown is attached to the previously optimized DNA sequence. The CDS in the following table correspond to sequences in the attached Sequence Listing, as shown below:

Starting Amino Acid	<u>CDS</u>	Test Sequence
<u>1 E</u>	<b>SEQ ID NO: 11</b>	bases 1-9 of SEQ ID NO: 9
<u>2 Q</u>	<b>SEQ ID NO: 12</b>	bases 1-12 of SEQ ID NO: 9
<u>3 F</u>	<b>SEQ ID NO: 13</b>	bases 1-15 of SEQ ID NO: 9
<u>4 I</u>	<b>SEQ ID NO: 14</b>	bases 1-18 of SEQ ID NO: 9
<u>4 I</u> <u>5 I</u>	SEQ ID NO: 15	bases 1-21 of SEQ ID NO: 9
<u>6 K</u>	<b>SEQ ID NO: 16</b>	bases 1-24 of SEQ ID NO: 9
<u>7 N</u>	<b>SEQ ID NO: 17</b>	bases 1-27 of SEQ ID NO: 9
<u>8 M</u>	<b>SEQ ID NO: 18</b>	bases 1-30 of SEQ ID NO: 9
<u>9 F</u>	<b>SEQ ID NO: 19</b>	bases 1-33 of SEQ ID NO: 9
<u>10 I</u>	SEQ ID NO: 20	bases 1-36 of SEQ ID NO: 9
<u>11 I</u>	SEQ ID NO: 21	bases 1-39 of SEQ ID NO: 9
<u>12 K</u>	SEQ ID NO: 22	bases 1-42 of SEQ ID NO: 9

Serial No.: 10/539,208 Attorney's Docket No.: B&B-135

Art Unit: Unknown Page 4

Inventor: David RAAB et al.

On page 53, please replace the paragraph beginning on line 6 with the following:

Origin of the amino acid sequence (SEQ ID NO: 23):

DEFINITION Aequorea victoria green-fluorescent protein mRNA, complete cds.

ACCESSION M62654

MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFSYGVQCFSRYP DHMKQHDFFKSAMPEGYVQERTIFYKDDGNYKSRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKMEYNYNSHNV YIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMILLEFVT AAGITHGMDELYK

On page 58, please add the following paragraph after the table at line 12:

The following sequences in the tables above correspond to sequences in the attached Sequence Listing: Eukaria: (consensus) Spice Acceptor (SEQ ID NO: 24); Eukaria: RNA inhib. Sequence (SEQ ID NO: 25); Prokaria: RBS-Entry (2) (SEQ ID NO: 26); Prokaria: RBS-Entry (1) (SEQ ID NO: 27); Prokaria: RBS-Entry (3) (SEQ ID NO: 28); Prokaria: RBS-Entry (4) (SEQ ID NO: 29); Prokaria: RBS-Entry (5) (SEQ ID NO: 30); Prokaria: RBS-Entry (6) (SEQ ID NO: 31); Prokaria: RBS-Entry (7) (SEQ ID NO: 32).

On page 65, please replace the heading at lines 1-3 with the following:

Annex: SEQ-IDs and alignments of the DNA sequences used

The SEQ-ID references used herein correspond to the similarly-numbered sequences in the attached Sequence Listing, e.g., "SEQ-ID1" corresponds to SEQ ID NO: 1, "SEQ-ID2" corresponds to SEQ ID NO: 2, etc.

SEQ-ID of the indicated constructs:

Serial No.: 10/539,208 Attorney's Docket No.: B&B-135
Art Unit: Unknown Page 5

Inventor: David RAAB et al.

Following the abstract, please replace the original Sequence Listing with the Substitute Sequence Listing attached hereto as substitute sheets (10 pages).